Skip to main content

Hyperbilirubinemia

2
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
1
Home Nurse VisitPhase 31 trial
tin mesoporphyrinPhase 21 trial
Active Trials
NCT00004382Completed80
NCT00360204Completed1,154Est. Feb 2010
Pediatrix Therapeutics
Pediatrix TherapeuticsChina - Shanghai
2 programs
Gene mutation sampleN/A1 trial
TcB MeasurementN/A1 trial
Active Trials
NCT00383318Completed450Est. Dec 2007
NCT03195998Completed166Est. Feb 2019
GE HealthCare
1 program
LED fiberoptic blanket phototherapyN/A1 trial
Active Trials
NCT00635375Completed82Est. Aug 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesHome Nurse Visit
Human BioSciencestin mesoporphyrin
Pediatrix TherapeuticsTcB Measurement
GE HealthCareLED fiberoptic blanket phototherapy
Pediatrix TherapeuticsGene mutation sample

Clinical Trials (5)

Total enrollment: 1,932 patients across 5 trials

NCT00360204Human BioSciencesHome Nurse Visit

Improving Health Outcomes for New Mothers and Babies

Start: Sep 2006Est. completion: Feb 20101,154 patients
Phase 3Completed
NCT00004382Human BioSciencestin mesoporphyrin

Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns

Start: Dec 199980 patients
Phase 2Completed
NCT03195998Pediatrix TherapeuticsTcB Measurement

Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants

Start: Jun 2017Est. completion: Feb 2019166 patients
N/ACompleted
NCT00635375GE HealthCareLED fiberoptic blanket phototherapy

Comparative Study of Phototherapy for Hyperbilirubinemia

Start: Mar 2008Est. completion: Aug 200882 patients
N/ACompleted
NCT00383318Pediatrix TherapeuticsGene mutation sample

Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

Start: Sep 2006Est. completion: Dec 2007450 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.